He described his previous statement that states should not use the vaccine in any age group as a misinterpretation of the Italian daily La Stampa, which published it on Sunday.
–
“All EMA-approved vaccines, including those from AstraZeneca, have a favorable benefit-risk balance, especially for the elderly and vulnerable, and should therefore continue to be used,” Cavaleri told ANSA. According to him, nothing changes even in terms of the age of people.
–
The vaccine is approved by the regulator for all persons over 18 years of age. However, the regulator will deal with new reported cases of anomalous blood clots in people who received the product from the British-Swedish society.
–
According to Cavaleri, the results of the new analyzes will be completed in July. The representative of the regulator emphasized that each country is free to decide how to use the supplied vaccines.
–
“Unfortunately, my statements in a recent interview with (the daily La Stampa) were not interpreted correctly,” Cavaleri told Reuters. According to the European agency, the conversation caused a lot of misinformation. “We therefore ask that articles containing incorrect information be updated,” EMA said on Monday.
–
Many European countries restrict the use of the British-Swedish vaccine due to the presence of blood clots. The Greek Vaccination Committee today recommended that the substance not be given to people under the age of 60. Italian Health Minister Roberto Speranza said on Friday that Italy would only vaccinate people over the age of 60 with the substance.
–
An eighteen-year-old death caused blood clots in an 18-year-old girl who was vaccinated with British-Swedish society a few days before her death caused a stir. The Czech Ministry of Health has also recommended that this vaccine not be given to people under the age of 60 since last week.
—
